Silo Pharma Licenses Promising Alzheimer’s Disease Therapeutic from Columbia University

NEW YORK- Silo Pharma, Inc. a biopharmaceutical company specializing in novel formulations and drug delivery systems, has announced its decision to license a therapeutic candidate for Alzheimer’s disease (AD), known as SPC-14, from Columbia University. This move follows a sponsored research and option agreement established in 2021.

Under the terms of the impending license agreement, Silo Pharma will acquire an exclusive global license to further develop, manufacture, and commercialize SPC-14. The company anticipates finalizing and entering into this exclusive license agreement in the first half of 2024.

Eric Weisblum, CEO of Silo Pharma, expressed optimism about the potential of SPC-14, stating, “Columbia University has discovered a therapeutic candidate that could bring relief and hope for Alzheimer’s patients and families.” He highlighted the inadequacy of current treatments for AD and the promising results of SPC-14 in preclinical studies, which showed cognitive improvement and stress reduction.

The Alzheimer’s disease therapeutics market is projected to surpass $30.8 billion by 2033, with a compound annual growth rate (CAGR) of 18.8% from 2024 to 2033. Factors such as the increasing prevalence of the disease in the aging population and advancements in neurological research are expected to contribute to market growth. Silo Pharma’s licensing of SPC-14 represents a significant step in addressing the needs of this expanding market.